STERIS (NYSE:STE) Cut to Buy at Wall Street Zen

STERIS (NYSE:STE) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Other research analysts have also issued reports about the stock. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. KeyCorp decreased their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a research note on Thursday, May 21st. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

STERIS Stock Down 0.1%

Shares of STERIS stock opened at $212.13 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The company has a 50-day moving average of $217.24 and a 200 day moving average of $239.09. The firm has a market cap of $20.70 billion, a price-to-earnings ratio of 26.75 and a beta of 0.93. STERIS has a 1 year low of $195.14 and a 1 year high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, sell-side analysts anticipate that STERIS will post 11.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the completion of the sale, the director directly owned 38,964 shares in the company, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.07% of the company’s stock.

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently bought and sold shares of STE. Board of the Pension Protection Fund bought a new stake in shares of STERIS in the fourth quarter worth approximately $25,000. Activest Wealth Management grew its stake in shares of STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 89 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of STERIS in the fourth quarter worth approximately $28,000. Harbor Investment Advisory LLC grew its stake in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 60 shares during the period. Finally, Western Wealth Management LLC bought a new stake in shares of STERIS in the first quarter worth approximately $25,000. 94.69% of the stock is currently owned by institutional investors.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.